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ABSTRACT
It is only within the last ten years that
research on treatment for central nervous
system (CNS) recovery after injury has become
more focused on the complexities involved in
promoting recovery from brain injury when the
CNS is viewed as an integrated and dynamic
system. There have been major advances in
research in recovery over the last decade,
including new information on the mechanics
and genetics of metabolism and chemical
activity, the definition of excitotoxic effects and
the discovery that the brain itself secretes
complex proteins, peptides and hormones which
are capable of directly stimulating the repair of
damaged neurons or blocking some of the
degenerative processes caused by the injury
cascade. Many of these agents, plus other non-
toxic naturally occurring substances, are being
tested as treatment for brain injury. Further
work is needed to determine appropriate
combinations of treatments and optimum times
of administration with respect to the time course
of the CNS disorder. In order to understand the
mechanisms that mediate traumatic brain injury
and repair, there must be a merging of findings
from neurochemical studies with data from
intensive behavioral testing.
INTRODUCTION: CURRENT PERSPECTIVES
This review begins with the assumption that
agents which promote functional recovery from
traumatic brain injury produce effects not only at
the site of the injury, but throughout the central
This article is an adaptation of a chapter to appear in
Christensen, A.-L. & Uzzell, B.P. "Neuropyschological
Rehabilitation", L. Erlbaum Publishers, Englewood (1993),
with permission.
nervous system. A corollary of that view is that
symptoms, syndromes and the behavioral recovery
following brain injury, depend very much upon the
context in which the injury occurred and not just on
the site of the injury itself. By "context", we mean
factors such as: age and prior health status of the
subject at the time of injury, gender of the patient,
hormonal conditions and indeed, even the
environmental conditions under which the subject is
raised. All such factors can play a role in
determining the success or failure of treatments
designed to promote recovery. This contextual issue
has gained in importance as more sophisticated
assessment and evaluation techniques permit access
to increasingly better, non-invasive views of the
functional and metabolic activity in the living brain.
For example, progress has been made in brain
imaging techniques that would seem to permit one
to "localize the injury" and by extension, assign the
nature of the deficit to the damaged tissue itself.
Despite these new methods, we would reiterate that
environmental and organismic variables must be
taken into account in deciding upon the prognosis
for recovery as well as for the course of
rehabilitation therapy provided for the patient.
Although this focus on a more holistic
perspective can be seen as a point more appropriate
for academic discussion than clinical practice, it is
an important theoretical issue not only for
academicians, but also for those directly involved in
treatment of brain injured patients. The issue of
plasticity lies at the heart of thinking about how the
nervous system is organized, how "plastic"
responses may be engendered aPter injury, and how
appropriate treatment strategies may be developed
and employed.
It is only within the last ten years that some
neurologists and neuropsychologists involved with
head injury have become more focused on the
complexities involved in promoting recovery from
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brain injury when the CNS is viewed as an
integrated and dynamic system. Prior to this, the
main task in dealing with head trauma was first to
stabilize the patient and then to diagnose and, in the
process, localize the deficits. In general, follow-up
therapy was left to rehabilitation specialists and
physiatrists whose basic task was to enable the
patient to compensate for and cope with his/her
disability rather than to promote functional recovery
per se. Thus, while a change in attitude about CNS
organization is slowly taking place, much emphasis
in neuroscience is still on identifying pathways,
chemical assays of specific brain regions and the
demonstration and perfection of exquisite,
hodological techniques. Given this molecular
perspective, it is not surprising that a widely read
textbook in medical neuroscience/32: p. 15/states
that:
"...all behavior, including higher mental
functioning (affective as well as cognitive),
can be localized to specific regions or
constellations of regions within the brain.
Descriptive neuroanatomy provides us with a
functional guide to local sites within the brain
that correspond to specific behaviors." (our
underline)
The focus on molecular techniques and upon
ever smaller units of function and brain cartography
which characterize current thinking about the brain
overlooks the fact that it is a patient who has brain
damage and not just a region of the brain itself.
Clearly, the mechanistic-reductionist perspective
offers small hope to patients and provides little basis
for formation and testing of hypotheses about the
diverse mechanisms underlying functional recovery
and CNS repair.
Conceptual development, requiring detailed
behavioral assessment, the hallmark of experimental
neuropsychology, has given way to an emphasis on
map-making and highly localized molecular
structure and function. Indeed, the state-of-the-art
of behavioral work associated with treatment for
recovery from injury was noted by the authors of a
best-selling neuropharmacology text book/16: p.4/,
who state that:
"...at the molecular level, an explanation of
the action of a drug is oen possible, at the
cellular level, an explanation is sometimes
possible, but at a behavioral level, our
ignorance is abysmal."
Current imaging techniques lend themselves to
focusing on the tree instead of the forest and
emphasize localization of various activities in
response to injury rather than a more systemic
change occurring throughout the brain as it
undergoes the process of reorganization and repair.
In metabolic studies, investigators often focus only
upon the most intense alterations observed during a
given behavior or aer an injury. They may ignore
the overall pattern and interplay of less intense
changes that occur both in the affected hemisphere
as well as on the side contralateral to the injury
itself. Several recent positron emission tomography
(PET) studies of regional cerebral blood flow in
patients recovering from stroke/14,62/demonstrate
significantly different patterns of activation from
those of normal subjects. Importantly, the patterns
are shown to be evoked in numerous brain
structures involving the whole brain, not just in a
few structures to which the deficit might be thought
to be "localized".
The elucidation of the mechanisms underlying
traumatic brain injury and repair will come from a
merging of the findings of molecular biology and
neurochemistry concerning alterations in the whole
brain with data from intensive behavioral testing, in
both human and animal models. In order to
understand the subtleties of CNS mechanism and
repair, we will need to look carefully at molecular
and "localized" findings in conjunction with
concomitant distal alterations, and, importantly, we
must evaluate these findings in light of their
observed effects on multiple standardized behavioral
tasks.
ADVANCES IN PHARMACOLOGICAL
APPLICATIONS TO BRAIN INJURY
There have been major advances in research on
recovery from brain damage over the last decade.
Although few, if any, specific pharmacologic
treatments for brain injuries are yet on the market,
we how have a much broader understanding of the
mechanics and genetics of metabolism and chemical
activity in neurons and glial cells. This new
information has led to a burst of pre-clinical
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research activity to develop new substances
designed to treat brain injury. In fact, in the past
five years there has been a dramatic increase in the
number of new biotechnology companies whose
specific purpose is to develop new drugs for
treating brain injury.
Only a short time ago most research on the
pharmacology ofCNS plasticity was directed to the
study of describing how neurons regulate the
release and metabolism of neurotransmitters, whose
loss or return was the sine qua non for restitution of
function. More recent efforts in this field now stress
the discovery and characterization of new agents
that modulate both neuronal and glial activity under
normal and disrupted conditions. Much more
emphasis is being placed on the discovery of
receptors on both neurons and glial cells and their
interdependence in neurotransmitter and
neuropeptide release/6,56,38/, in responses which
can influence how the nervous system adapts to
environmental conditions and to trauma.
With respect to the development of a specific
pharmacology of recovery from brain damage over
the last decade, we believe that there were several
fundamentally important areas of research that have
had an impact. First, it was confirmed that amino
acids involved in CNS metabolism also might serve
as neurotransmitters in their own right. In fact,
Cooper, Bloom and Roth/16: p. 124/state that:
"...from a quantitative standpoint (i.e.
amounts present in the brain), the amino acids
are probably the major neurotransmitters in
the mammalian CNS, while the better-known
transmitters (acetylcholine, dopamine, etc.)
probably account for transmission at only a
small percentage of central synaptic sites."
Investigators soon found that the amino acids
are not just important for regulation and control of
neurotransmission under normal conditions. In a
second major research development, it was
determined that traumatic brain injury often results
in the excessive release of excitatory amino acids
such as glutamate. The term ’excessive’ is used
because, in higher amounts, the same substances
required for neural transmission become "toxic" and
cause neural death/43,21/. The secondary effects of
injury may actually be more responsible for some of
the behavioral deficits accompanying the trauma
than the initial trauma itself. In particular, stroke,
ischemia or direct injury to the brain produces a
"glutamate cascade" culminating in an excess of
calcium ions entering into vulnerable neurons and
destroying them (for details of the process, see the
excellent review ofZivin and Choi/67/).
Once the pathways for the excitotoxic effects of
amino acid neurotransmitters had been determined
at the beginning of the decade, it then became
feasible to develop specific compounds which could
be used to antagonize and block the excitotoxic
cascade of events leading to cell death and thus
possibly prevent the loss of behavioral functions
associated with the damage. For example, there are
now agents available which block (antagonize)
neuronal glutamate receptors and thus prevent
calcium ion toxicity/7,40,60/. The effects of these
drugs are to reduce the production of free radical
peroxidation, cerebral edema and the resultant
necrosis of brain tissue and to attenuate behavioral
impairments.
Blocking some of the secondary destructive
effects of ions and their toxic by-products, such as
free radicals, promises to be a major step in the
treatment of brain injury /39/. By quenching the
chain reactions initiated by these toxic compounds,
CNS protection can be conferred at many different
levels. Thus, the hope is to limit the chemical
reactions that lead to the spread of secondary injury.
The sites of free radical attack occur mainly in the
lipid membranes of vascular endothelial cells, glia,
and neurons, disrupting their structure and function.
In the case of the endothelial cells, their disruption
leads to the breakdown of the blood-brain barrier
(BBB), allowing many other generators of free
radicals (such as iron, excitatory amino acids, and
clotting factors) to enter the brain, causing edema
and further tissue destruction. The disruption of the
BBB can also facilitate exposure of the brain to
blood macrophages and subsequent autoimmune
phenomena or non-specific injury. Macrophages
possess enzymes in their membranes that produce
highly reactive free radicals which can severely
damage cell membrane structure. Disruption of
neuronal function can be caused by demyelination of
axons as well as alterations of membrane fluidity
affecting receptors and metabolic enzymes.
In order to block some of these destructive
events, our laboratory has studied the effects of
alpha tocopherol (vitamin E) on behavioral and
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anatomical recovery following aspiration injury to
the frontal cortex in rats. Our results/54/show that
direct application of alpha tocopherol to the wound
cavity produces both an increased rate of recovery
on a learning task and sparing of neuronal tissue,
i.e. higher neuronal counts, smaller ventricle size,
and reduced gliosis. In another study by Clifton and
coworkers/15/, the systemic administration of an
alpha tocopherol derivative had significant
protective effects when injected either before or
after a fluid percussion injury of the cortex in rats.
This derivative significantly reduced mortality rate
and increased the rate of motor recovery. These
two studies demonstrate the ability of vitamin E (as
alpha tocopherol or a derivative) to alleviate deficits
following traumatic insult to the brain. Walsh also
reports similar effects with vitamin E in this
symposium. The advantages of working with this
substance are that it is easily available, inexpensive
and, as far as is known, safe to use.
Another substance that is of plant origin and that
has produced beneficial results in both clinical and
experimental studies is EGb 761, an extract of the
tree Ginkgo biloba. This substance consists ofmany
different compounds called ginkgolides that have
antioxidant properties and can inhibit the actions of
substances that adversely affect the permeability of
the blood-brain barrier/9,42/. In our laboratory we
have found that treatment with EBb 761 in rats
given bilateral frontal cortex aspirations produced
significant behavioral improvements on a spatial
learning task/2/. Rats given EGb 761 made fewer
errors and perseverated less frequently to the
incorrect side of a T-maze than their lesion-only
counterparts and they also showed more normal
exploration behavior in an open-field maze.
Anatomical analyses revealed that the treatment
with EGb 761 reduced ventricular size, suggesting
that EGb 761 prevented the development of
cerebral edema. Recently, Brailowsky and
coworkers /8/ reported similar effects of EGb 761
in ameliorating the effects of cortical hemiplegia in
rats with either motor cortex aspiration lesions or
cortical depression produced by injection of
gamma-aminobutyric acid (a neurotransmitter) into
the brain. In the experiments by Brailowsky and
coworkers, both types of "injury" produced short-
term deficits in motor behavior and in both injury
models, chronic EGb 761 administration reduced
the duration of the behavioral deficits, although the
effects of the treatments were more clearly seen
after the mechanical injury. Although this line of
research is still quite new, it does demonstrate that
recovery from traumatic brain injury can be
facilitated by administration of relatively benign,
naturally occurring substances that pose little threat
to the organism.
Concomitant with increased understanding of
the normal and post-injury effects of amino acid
neurotransmitters, with resultant possibilities for
pharmacological intervention, a third major research
step occurred which had an impact on the field of
pharmacology of recovery from brain damage. The
discovery was made that, in response to damage,
the brain itself secretes complex proteins, peptides
and hormones which are capable of directly
stimulating the repair of damaged neurons/5,17,36/
or blocking some of the degenerative processes
caused by the injury cascade. Substances which
stimulate new neuronal growth and/or help to
restore damaged membranes are called
"neurotrophic agents". When trophic substances are
extracted from the brain and placed into culture
dishes containing neurons, they keep the cells from
dying and actually promote growth of new
processes. In vivo, trophic factors may serve to
guide regenerating or sprouting terminals to their
appropriate target areas in the brain /4,30,35/.
Trophic factors appear to have their highest
concentrations at or near sites of injury and they
reach their peak about one week post-injury,
thereafter declining in concentration and activity
/17/. Research in the area of trophic factors has
produced increased understanding of endogenous
mechanisms of recovery, and stimulated interest in
pharmacological applications of trophic factors aer
brain damage.
Some researchers have argued that injury-
induced activation of specific glial cells is of primary
importance in the production of neurotrophic agents
after damage to the CNS/28/. This hypothesis has
resulted in consideration of the "beneficial" role of
glia in promoting brain injury repair and functional
recovery. While the eventual formation of a glial
scar is thought to be detrimental to recovery, initial
effects may be beneficial /63/. One suggested
mechanism for a positive effect is through injury-
induced activation of astrocytic glia cells, with
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subsequent expression and production of nerve
growth factor (NGF), which promotes cholinergic
sprouting responses/22,28/.
The discovery of endogenous, brain-derived,
trophic factors which appear to affect neural growth
and viability has led to the premise that some
degenerative disorders such as Alzheimer’s disease
(AD) might be treatable with specific factors which
selectively affect neurons known to figure
importantly in systems which become dysfunctional.
For example, it has been proposed that treatment
with NGF might serve to alleviate a basal forebrain
cholinergic deficit which may underlie the loss of
cognitive function seen in AD/30,44/. The potential
for therapeutic use of these proteins has encouraged
a number of pharmaceutical and biotechnology
companies to find ways of synthesizing trophic
factors or genetically engineering cells that can be
grown and modified in culture and are capable of
producing commercial quantities of substances
which might be needed by an injured brain. Altered
cells could replace not only trophic factors, but also
neurotransmitters or hormones, which could then be
provided to patients on a regular basis/10,13,27/.
For example, recent intracerebral application of
genetically modified fibroblast cells expressing NGF
/46/prevented degeneration in 92% of cholinergic
neurons subjected to fimbria fornix lesion.
However, we must emphasize that there are
grounds for caution and especially for further
research in animals before treatments can be applied
to humans. Pressure from special interest groups
and seriously ill patients who (understandably)
demand rapid application before all the facts are
known has led to clinical trials before careful
assessment of the long-term effects of treatments
has been determined in the laboratory. A good
example of this approach is the attempt to provide
intracerebral injections of NGF directly to patients
with Alzheimer’s disease. To date, there is no
effective way to arrest the cognitive deterioration of
these patients. It has been proposed that treatment
with NGF might serve to alleviate a basal forebrain
cholinergic deficit which may underlie the loss of
cognitive function seen in AD /30/. However, an
alternative hypothesis concerning the etiology of
AD has been proposed /12/, which suggests that
AD may be initiated by changes in regulatory
mechanisms which are responsible for sequential
expression of cytoskeletal protein in neurons
normally exhibiting structural plasticity. In this
hypothesis, certain proteins providing cytoskeletal
stabilization are negatively affected, while normally
labile proteins remain active. The result of this
process is postulated to be a cascade of neural
abnormalities, reactive gliosis, and eventual neural
degeneration. Thus the putative breakdown in
plasticity components and loss of effectiveness of
stable cytoskeletal proteins leads to the occurrence
of neurofibrillary plaques and tangles in AD brains,
which are associated with resultant cognitive loss.
From this perspective, NGF therapy could
exacerbate the abnormal growth, and drugs that
block NGF synthesis or NGF receptors would be
more beneficial in the early stages of AD. These
ideas can be taken to suggest that treatments
entirely appropriate for one type of injury, such as
trauma, or at one stage of development (e.g. young
adults), might be completely contraindicated for
treatment of other diseases, such as degenerative
disorders, or under other conditions (e.g. aged
subjects).
STUDIES OF SYSTEMIC ADMINISTRATION OF
SUBSTANCES WITH NEUROTROPHIC EFFECTS
Despite the clear need for caution in
extrapolating from pre-clinical studies to the human
patient, there are several promising lines of research
on the use of trophic factors to promote functional
recovery from a variety of traumatic brain injuries.
For example, in our laboratory, we have taken the
approach of identifying and employing experimental
substances which: (a) are effective in the early
stages of the injury process; (b) are naturally
occurring substances which do not appear to have
toxic side effects even at relatively high doses; (c)
can pass the blood-brain barrier, and thus can be
repeatedly administered systemically rather than
intracerebrally, and (d) have identifiable
physiological or histological/anatomical correlates
that can be measured and quantified.
In addition to the use of alpha tocopherol and
EGb 761, we have also used a synthetic portion of
the peptide hormone adrenocorticotropin (ACTH)
as treatment for brain injury. ACTH plays a role in
stimulating the adrenal gland to produce
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corticosteroids which, in turn, affect vital functions
such as energy metabolism, fluid regulation, and
response to stress. ACTH fragments have also been
used to enhance cognition and reverse deficits after
brain damage /18,65,66/. At the physiological level,
Richter-Landsburg, Bruns and Flohr /45/ have
shown that ACTH fragments promote neurite
growth in vitro. It is possible that a similar
compound might also protect neurons that would
ordinarily die as a consequence of frontal cortex
lesions. Further, Strand et al. /55/ found that
different ACTH analogs had the ability to facilitate
the regeneration of peripheral nerves, offering the
possibility that these compounds could initiate
repair in the damaged CNS. We reasoned that such
protection would also result in behavioral recovery
of a spatial learning task that is severely impaired
after frontal cortex injury. In our experiments, we
used BIM-22015 (which is a structural analog of
ACTH4.0), injected subcutaneously. Our research
indicates that BIM-22015 increased the rate of
behavioral recovery on a spatial learning task, and
the improved performance was accompanied by the
sparing of cholinergic neurons in the nucleus basalis
magnocellularis /1/. Positive behavioral effects of
other ACTH analogs have also been demonstrated
by Wolterink et al./65,66/aider chemical lesions to
the nucleus accumbens. Their results indicated that
the behavioral recovery was not a function of
increased activity in the dopaminergic system, but
rather of the increased sensitivity of dopamine
receptors, which increased the efficiency of the
remaining synapses. Recently, Goldman et al. /29/
have reported that their analog GMM increased
cerebral blood flow and decreased vascular
permeability, thus decreasing intracranial pressure
after closed head injury in rats. It should be said,
however, that all these studies support a role for
ACTH analogs in the treatment of head injury, but
as in the case of vitamin E, the beneficial effects of
ACTH analog therapy were more pronounced when
the treatment was given soon afier the injury.
Our laboratory has also utilized ganglioside
GM1, an endogenous glycolipid, in treatment for
several types of brain injury. Systemic injections of
gangliosides to rats with lesions of the caudate
nucleus resulted in a significant reduction of
impairment in a battery of behavioral tests designed
to reveal the deficits shown by untreated rats with
this injury /48/. matomical analysis of these
subjects revealed early enhancement of neuronal
reorganization with treatment/49/, a finding similar
to the results of GM1 treatment ater nigrostriatal
lesion /47/, where reduction of neuronal
degeneration was seen. Systemic administration of
GM1 has been shown to ameliorate behavioral
deficits after discrete lesion of a diverse number of
brain regions /20,52,58,61/. In an exciting recent
finding, GM1 treatment was given to non-human
primates with MPTP-induced parkinsonian
syndrome (PS) /53/. Not only were dopaminergic
levels significantly increased over untreated animals,
but also the acute motor problems characterizing PS
were ameliorated.
Although understanding of the mechanism of
gangliosides’ action in normal and in injured tissue is
not yet complete, they have been implicated in a
number of roles. A partial listing includes
modulation of neural regeneration/24,49/, possible
inhibition of lipid peroxidation /57/, membrane
stabilization /23,34/ and protection of ion pumps
and channels found in the cell membrane (for
reviews, see/33,52/). Additionally, current research
is exploring a possible involvement of gangliosides
in modulation of the effects of endogenous growth
factors, such as NGF or epidermal growth factor
(EGF)/11,19,52/.
ADDITIONAL FACTORS FOR CONSIDERATION
Because the injury cascade takes place over time
and always in the context of the organism’s
environment, health status and individual learning
and emotional history, these variables, in addition to
pharmacologic treatment, will play an important
role in determining the success or failure of any
medical or psychological therapy. It is also
becoming increasingly clear that gender may be a
significant contributing factor to the processes of
cerebral plasticity and any concomitant recovery
that can occur in response to brain damage. Gender
considerations may also be important in determining
the appropriate course of pharmacological therapy
for brain damage because the response to drug-
hormone interactions may be very different for
males and females or for pre- or post-menopausal
females. There are virtually no clinical studies in this
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area, although gender-related differences in
response to injury have been shown/37,59/and a
relationship between the hormonal status of females
at the time of brain injury and the severity of the
deficit has been demonstrated/3/.
As researchers have learned more about the
complexity of the injury-recovery cycle, awareness
has been growing of the injury continuum.
Especially in CNS injury, an initial insult has not
only immediate consequences, but also results in
differing morphological and chemical alterations at
later stages aer injury. Researchers have thus
begun to focus on the different stages of the injury
process to determine which specific agents might be
most effective in blocking neuronal loss and
functional impairments and when they should be
administered. As mentioned earlier, a substance
indicated for treatment in an early stage ofthe injury
process might be ineffective, or actually
counterproductive, at a later stage. For example, the
potential for survival of striatal transplants into
damaged cortical tissue coincides with the period of
peak, endogenous trophic factor expression /41/.
Recent research with diazepam also stresses the
importance of matching administration of treatment
to the stage of injury. When diazepam (a
GABAergic agonist) was given to rats for several
weeks after specific brain injuries, neural
degeneration was markedly enhanced and no
behavioral recovery could be observed at any time
during the testing period, whereas animals not given
diazepam were able to show normal recovery within
a week after injury/50,51/. Importantly, continued
administration of diazepam for three weeks, begun
immediately aRer injury, prevented behavioral
recovery for three months (the length of the
experiment), although the treatment had been
discontinued/51/. It is quite possible that diazepam
begun later in the continuum of the injury would
have a different effect. It is worthwhile noting that
diazepam or its related compounds are often given
to patients with stroke or CNS trauma, immediately
after injury, in order to reduce post-injury agitation
and help to "stabilize" them. Therefore, we must
consider that proper treatments require more
complex tailoring to the individual needs of the
subject. Not only the type of injury, but also its
projected time course, subject-specific variables and
the pharmacological consequences of multiple,
successive CNS alterations must be considered.
CONCLUSIONS
Defining recovery
Although we have learned a great deal about the
cascade of evems and processes that we now call
"brain injury", and although we have made great
strides in developing new pharmacological agents to
modify and control these events, there are still
considerable gaps in our knowledge of functional
recovery. While much has been written about
functional recovery, workers in this field still do not
have available a clear and precise definition of what
is meant by the term itself. As the time course of
functional recovery may be very long, or the
functional recovery may be incomplete or result in
different behaviors than in the pre-morbid state,
who should define recovery and what criteria should
be used? Physicians, social workers, the families of
patients, insurers, and employers will all have their
own standards for recovery, based on different
needs. In deciding the criteria for adequate
functional recovery, optimum medical practice may
be overshadowed by economic, political and social
considerations.
Defining the injury
As we noted above, there is a complex series of
events that occurs following brain injury. However,
the nature of these events may differ in a variety of
ways from one type of injury to another. For
example, some injuries, like contusions, may cause
extensive disruption of the blood-brain barrier (e.g.
closed head injury) and may leave the brain open to
immunological attack. This immunological response
can result in increased edema, demyelination, and
neuronal death. In those injuries that leave the BBB
more-or-less intact, as is the case with excitotoxic
lesions, there may be a cascade that is less diffuse
and extensive, consequently producing a more
localized injury requiring less complex or extended
treatment. The type of injury sustained will
determine what specific pharmacologic agents
should be used, and when they should be employed
in the injury-repair cycle. Case management in the
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early stage must include a careful and detailed
evaluation of the injury itself and define the most
effective treatments to employ.
Evaluating the outcome of rehabilitation and therapy
Whether rehabilitation therapy takes the form of
pharmacological manipulation of the CNS,
behavioral modification techniques, or some
combination of both, there must be detailed and
comprehensive follow-up evaluations of functional
outcomes. Carefully planned studies should be
developed in collaboration with the various
specialists involved in the therapeutic program. It
will be necessary to compare distinct components of
the treatments to determine which are most
effective and which can be eliminated. Standards for
measurement of clinical outcomes should be agreed
upon by the rehabilitation community and applied in
a manner that can demonstrate that the techniques
do, in fact, improve functional outcome and that
they meet the criteria for reliability (replicability)
and validity (can be shown to make a difference).
The question of validating treatment methods is
very much related to the issue of developing
meaningful and consistently employed measures of
functional recovery- issues that have yet to be
resolved by rehabilitation specialists. Given the high
costs of extended treatment for the brain-injured
patient, it is unlikely that social agencies or
companies providing payment for services will
continue to do so unless they can be assured that a
proposed professional medical/rehabilitation
program is most likely to provide the optimum
recovery available to the patient.
When is it appropriate to begin treatment
Ifwe have learned anything about treating brain
injury over these last years, it is that therapy to
promote functional recovery must begin as soon as
possible after the initial trauma. Delaying the course
of treatment to observe how much "spontaneous
recovery" is likely to occur, will, in most cases,
result in treatment failure. Inflammatory reactions,
edema, production of free radicals and excess
excitatory amino acids, for example, must be
eliminated before growth promoting and
regenerating factors can have their effects. At the
same time, psychological and social rehabilitation
should begin as soon as the patient can tolerate this
type of environmental stimulation.
What is the appropriate course of therapy?
There are many professionals who believe that
unless recovery occurs within a relatively short time
after injury, there will be no recovery at all. This is
not the whole story. Optimum recovery is much
more likely when treatment begins as early as
possible after injury, but there is a substantial
literature showing that recovery from aphasia and
certain motor disorders can take years. Unless one
is very fortunate, it is also the case that
combinations of therapeutic agents will be needed,
in both the early and later stages of injury, to treat
the various syndromes that are produced by
traumatic brain damage.
In the research laboratory, we examine single
agents in order to determine what specific,
physiological mechanisms are associated with the
functional recovery. As different pharmacological
agents are identified, it may be necessary to
combine agents to produce maximum beneficial
effects. Additionally, as more is learned about the
continuum of changes that occur ater an initial
insult to the CNS, we will be better able to alter
treatment to coincide with a "window of efficacy".
These fields of research have yet to be adequately
developed.
While it is true that a long course of medical and
psychosocial therapy may be expensive, it may
nonetheless be necessary if true functional recovery
is the goal. Such therapy must be conducted in a
positive, caring and enriched environment. Close
cooperation and coordination of treatments among
neurologists, physiatrists and rehabilitation
psychologists should be the norm and the standard
in the field of restorative neurology. Based upon
what we know from experiments in laboratory
animals /25,26,31,64/, environmental enrichment,
coupled with appropriate pharmacological
treatments, may hold out the best hope for
functional recovery in severely brain-injured
patients, but only if one is prepared to invest the
necessary time and effort to accomplish this goal.
In conclusion, there is no doubt that those
concerned with basic research in restorative
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neuroscience have made great progress in opening
new lines of inquiry and in developing a much better
understanding of the injury and recovery process.
Following the great strides in molecular biology,
many research laboratories and pharmaceutical
companies are beginning to identify or develop new
agents capable of protecting the nervous system or
facilitating recovery from brain injury. The selective
use of such biochemical agents with respect to
specific brain trauma and individual subject-related
variables, in combination with behavioral and
psychologically-oriented treatment methods, may
ultimately lead to a system of comprehensive
treatments tailored to various forms ofbrain injury.
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